Kingsview Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kingsview Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,710	Closed	-$221K	–	987
2023 Q3	$221K	Buy	+1,710	New	+$228K	0.01%	849
2023 Q2	–	Sell	-1,570	Closed	-$230K	–	947
2023 Q1	$230K	Buy	1,570 +7	+0.4%	+$1.03K	0.01%	794
2022 Q4	$249K	Sell	1,563 -4	-0.3%	-$586	0.01%	727
2022 Q3	$209K	Buy	1,567 +24	+2%	+$3.65K	0.01%	748
2022 Q2	$241K	Sell	1,543 -28	-2%	-$4.31K	0.01%	714
2022 Q1	$245K	Sell	1,571 -58	-4%	-$8.42K	0.01%	759
2021 Q4	$208K	Buy	1,629 +60	+4%	+$7.88K	0.01%	851
2021 Q3	$204K	Buy	+1,569	New	+$237K	0.01%	798

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kingsview Wealth Management's JAZZ Position: Q4 2023 in Review

Kingsview Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 1,710 shares — an estimated $221K sold.

Kingsview Wealth Management first reported a position in JAZZ in Q3 2021 and held it in 8 quarters. The position peaked at $249K in Q4 2022. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

Kingsview Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Kingsview Wealth Management sold 1,710 Jazz Pharmaceuticals shares in Q4 2023, an estimated $221K.
Kingsview Wealth Management first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Kingsview Wealth Management's Jazz Pharmaceuticals position peaked at $249K in Q4 2022.
500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Kingsview Wealth Management's 13F filing for Q4 2023, filed 8 Feb 2024.